Moderna Stock News

Der Pharmakonzern Pfizer musste in den vergangenen Jahren damit kämpfen, dass die COVID-19-bedingten Umsätze weggebrochen sind. Nun wird der Neuanfang gewagt.

Also: Technical analysis for trading in shares of Nvidia, how MicroStrategy burns cash, and tips for people with student loans in 2025

As 2024 is nearing its end, investors with a time machine are looking to visit December 2023 and take their long positions in Nvidia (NASDAQ: NVDA), Tesla (NASDAQ: TSLA), Super Micro Computer (NASDAQ: SMCI) – though with a sell order placed for April – and myriad Chinese stocks, again, with a sell order for October 1.

The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide. The global market for mRNA vaccines and therapeutics is expanding due to the rising incidence of chronic illnesses worldwide.

Der US-Pharmakonzern und Impfstoffhersteller Moderna US60770K1079 muss noch vor Weihnachten aus dem technologielastigen US-Aktienindex Nasdaq 100 US6311011026 weichen.

Moderna's (MRNA 3.13%) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years, a period during which the biotech has lost 85% of its value.

A five-bagger in only five years? Any investor would love to buy such a stock.

The incredible returns equity investors have seen in 2024, and over the past couple months for that matter, have been incredible.